vida: extract claims from 2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd

- Source: inbox/queue/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
- Domain: health
- Claims: 2, Entities: 2
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -10,12 +10,16 @@ agent: vida
 scope: causal
 sourcer: The Lancet Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-related:
-- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
-reweave_edges:
-- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation|related|2026-04-12
+related: ["Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse", "cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions"]
+reweave_edges: ["Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation|related|2026-04-12"]
 ---
 
 # Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
 
-Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.
+Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.
+
+## Extending Evidence
+
+**Source:** Compass Pathways COMP005 Phase 3 trial (n=258)
+
+Psilocybin inverts the continuous treatment model by producing 26-week durability from a single 25mg dose in treatment-resistant depression (MADRS -3.6, p<0.001), with psychological support embedded as a required protocol component (preparation, monitored session, integration) rather than optional relapse mitigation. This represents a fundamentally different pharmacological paradigm from daily-dosing antidepressants.

domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: COMP005 trial demonstrates MADRS -3.6 point improvement (p<0.001) with benefits maintained through 26 weeks from a single 25mg dose, marking the first psychedelic to reach Phase 3 efficacy threshold
+confidence: experimental
+source: Compass Pathways COMP005 Phase 3 trial (n=258, 32 US sites)
+created: 2026-05-10
+title: Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
+agent: vida
+sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
+scope: causal
+sourcer: Compass Pathways
+challenges: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
+---
+
+# Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
+
+The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.

domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: COMP005 trial protocol mandated preparation sessions, monitored dosing sessions, and post-session integration as required elements, indicating psilocybin efficacy depends on both pharmacological mechanism and structured psychological process
+confidence: experimental
+source: Compass Pathways COMP005 Phase 3 protocol design
+created: 2026-05-10
+title: Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
+agent: vida
+sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
+scope: structural
+sourcer: Compass Pathways
+supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+---
+
+# Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
+
+The COMP005 trial embedded psychological support as a mandatory protocol component across three phases: pre-session preparation, monitored dosing session (with trained facilitators present throughout the 6-8 hour experience), and post-session integration sessions. This design choice indicates that psilocybin therapy is not purely pharmacological but rather a hybrid intervention where the drug enables a psychological process that requires professional support to translate into clinical benefit. The trial's positive results cannot be attributed to the molecule alone but rather to the complete protocol package. This has significant implications for clinical implementation: psilocybin therapy will require specialized training infrastructure, dedicated session spaces, and multi-hour clinician time per patient—creating a fundamentally different delivery model than traditional psychiatric pharmacotherapy. The psychological support requirement also creates a natural quality control mechanism that may prevent the commoditization pathway seen with other psychiatric medications. This sits at the clinical/non-clinical interface: the pharmacological mechanism (5-HT2A agonism, neuroplasticity) is necessary but not sufficient; the psychological meaning-making process enabled by the drug state appears essential for durable benefit. The FDA approval pathway will need to specify not just the molecule but the complete therapeutic protocol, creating precedent for regulating hybrid pharmacological-psychological interventions.

entities/health/comp005-trial.md

@@ -0,0 +1,54 @@
+# COMP005 Phase 3 Trial
+
+**Sponsor:** Compass Pathways  
+**Intervention:** COMP360 psilocybin 25mg single dose  
+**Indication:** Treatment-resistant depression  
+**Status:** Completed, positive primary endpoint  
+**Reported:** June 23, 2025  
+
+## Trial Design
+
+- **Phase:** 3
+- **Design:** Randomized, double-blind, placebo-controlled
+- **Sample Size:** n=258
+- **Sites:** 32 sites in the United States
+- **Population:** Treatment-resistant depression (≥2 failed antidepressant courses)
+- **Intervention:** Single dose COMP360 25mg vs. placebo
+- **Protocol:** Embedded psychological support (preparation, monitored session, integration)
+
+## Primary Endpoint
+
+**MADRS change from baseline at Week 6:**
+- Treatment difference: **-3.6 points** (95% CI [-5.7, -1.5])
+- **p<0.001** (highly statistically significant)
+
+## Secondary Outcomes
+
+- **Response Rate:** 25% achieved clinically meaningful MADRS reduction (≥25%) at week 6
+- **Durability:** Improvement maintained through 26-week follow-up after single dose
+- **Rapid Onset:** Statistically significant benefit from next day after dosing
+
+## Safety Profile
+
+- All treatment-emergent adverse events: mild or moderate severity
+- Most adverse events resolved within 24 hours
+- Frequently reported: headache, nausea, anxiety, visual hallucination
+- No clinically meaningful imbalance in suicidal ideation between arms
+- No unexpected safety findings
+
+## Historical Significance
+
+- **First investigational psychedelic to report positive Phase 3 efficacy data**
+- First classic psychedelic to reach Phase 3 evidence level
+- Establishes proof-of-concept for FDA approval pathway for psychedelic therapeutics
+
+## Clinical Context
+
+- Effect size (-3.6 MADRS points) comparable to existing TRD augmentation strategies (2-4 points)
+- Single-dose 26-week durability represents paradigm shift from daily-dosing chronic treatment model
+- Psychological support protocol is mandatory component, not optional adjunct
+- Treatment-resistant depression population: ~7M Americans who have failed 2+ antidepressant courses
+
+## Timeline
+
+- **2025-06-23** — Primary endpoint results announced: MADRS -3.6 (p<0.001), first positive Phase 3 data for any psychedelic

entities/health/compass-pathways.md

@@ -0,0 +1,44 @@
+# Compass Pathways
+
+**Type:** Clinical-stage biopharmaceutical company  
+**Focus:** Mental health, psychedelic therapeutics  
+**Headquarters:** United Kingdom  
+**Lead Asset:** COMP360 (synthetic psilocybin)  
+
+## Overview
+
+Compass Pathways is a clinical-stage biopharmaceutical company developing COMP360, a proprietary synthetic psilocybin formulation for treatment-resistant depression and other mental health conditions. The company holds FDA Breakthrough Therapy Designation and reported the first positive Phase 3 efficacy data for any investigational psychedelic in June 2025.
+
+## Key Programs
+
+### COMP360 Psilocybin
+- **Indication:** Treatment-resistant depression (TRD)
+- **Mechanism:** 5-HT2A receptor agonism with embedded psychological support protocol
+- **Status:** Phase 3 (COMP005 positive, COMP006 pending)
+- **Regulatory:** FDA Breakthrough Therapy Designation, Commissioner National Priority Voucher (April 2026)
+
+## Clinical Evidence
+
+### COMP005 Phase 3 Trial
+- **Design:** Randomized, double-blind, placebo-controlled (n=258, 32 US sites)
+- **Population:** Treatment-resistant depression (≥2 failed antidepressant courses)
+- **Intervention:** Single dose COMP360 25mg vs. placebo with psychological support protocol
+- **Primary Endpoint:** MADRS change at Week 6: -3.6 points (95% CI [-5.7, -1.5], p<0.001)
+- **Durability:** Benefits maintained through 26-week follow-up from single dose
+- **Safety:** All adverse events mild-to-moderate, resolved within 24 hours
+
+## Regulatory Pathway
+
+- **NDA Filing:** Expected Q4 2026 (pending COMP006 26-week data)
+- **Breakthrough Designation:** Held for multiple years
+- **Priority Voucher:** Received April 24, 2026
+
+## Significance
+
+COMP005 represents the first Phase 3 evidence for a psychedelic drug and the first classic psychedelic to reach Phase 3 efficacy threshold, establishing proof-of-concept for FDA approval of the broader class.
+
+## Timeline
+
+- **2025-06-23** — COMP005 Phase 3 trial achieves primary endpoint with MADRS -3.6 point improvement (p<0.001), marking first positive Phase 3 data for any investigational psychedelic
+- **2026-04-24** — Receives Commissioner National Priority Voucher
+- **2026-Q4** — NDA filing expected (pending COMP006 data)

inbox/archive/health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md

@@ -7,10 +7,13 @@ date: 2025-06-23
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: high
 tags: [psilocybin, treatment-resistant-depression, Phase-3, clinical-trial, mental-health, psychedelic-therapy, FDA, Compass-Pathways]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content